Lirilumab: Ph II EffiKIR data

Top-line data from the double-blind, French Phase II EffiKIR trial in about 150 elderly AML patients in

Read the full 175 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE